MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis

PLoS One. 2014 Feb 14;9(2):e88745. doi: 10.1371/journal.pone.0088745. eCollection 2014.

Abstract

Introduction: Previous studies demonstrated that MicroRNA-92a (miR-92a) was significantly differential expressed between colorectal cancer (CRC) patients and control cohorts, which provide timely relevant evidence for miR-92a as a novel promising biomarker in the colorectal cancer patients. This meta-analysis aimed to evaluate potential diagnostic value of plasma miR-92a.

Methods: Relevant literatures were collected in PubMed, Embase, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI) and Technology of Chongqing (VIP), and Wan Fang Data. Sensitivity, specificity and diagnostic odds ratio (DOR) for miR-92a in the diagnosis of CRC were pooled using random effects models. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were used to estimate the overall test performance.

Results: This Meta-analysis included six studies with a total of 521 CRC patients and 379 healthy controls. For miR-92a, the pooled sensitivity, specificity and DOR to predict CRC patients were 76% (95% confidence interval [CI]: 72%-79%), 64% (95% confidence interval [CI]: 59%-69%) and 8.05 (95% CI: 3.50-18.56), respectively. In addition, the AUC of miR-92a in diagnosis CRC is 0.7720.

Conclusions: MicroRNA-92a might be a novel potential biomarker in the diagnosis of colorectal cancer, and more studies are needed to highlight the theoretical strengths.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Aged
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / genetics*
  • Genetic Heterogeneity
  • Humans
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Middle Aged
  • Publication Bias
  • ROC Curve
  • Regression Analysis

Substances

  • Biomarkers, Tumor
  • MIRN92 microRNA, human
  • MicroRNAs

Grants and funding

This work was supported in part by National Natural Science Foundation of China (NSFC 81072147, NSFC 30940096); the Doctoral Fund of Ministry of Education, China (20105503110001, 20125503110001); the Scientific Research Foundation for the Returned Overseas Chinese Scholars, Ministry of Education, China ( [2011]508); the Major Program of Chongqing Medical University XBZD201006; and the Scientific Research Foundation for the Returned Overseas Scholars of Chongqing Medical University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.